About Us

The National Center for Biomedical Glycomics interacts with the scientific community in five primary ways:

  1.  Service
  2.  Training
  3.  Driving Biomedical Projects
  4.  Collaborations
  5.  Industry Partnerships

Service: We have a robust service program that analyzes glycan and glycoconjugate samples from investigators around the world. Technologies that we have developed are incorporated into our service program, such as analysis of glyco-gene expression by qRT-PCR and Next-Gen Sequencing. Please contact Parastoo Azadi at azadi@uga.edu for more information.

Training: We offer hands-on training in techniques and methodology for analysis of particular glycoconjugates through workshops held at the Complex Carbohydrate Research Center; moreover, we offer brief courses as part of several scientific meetings. Please contact Parastoo Azadi at azadi@uga.edu for more information.

Driving Biomedical Projects: We partner with investigator-initiated projects that drive the development of various glycomic technologies.  If you are interested in discussing potential DBP, please contact Michael Pierce at hawkeye@uga.edu for more information.

Collaborations: These projects are initiated through interactions with our service program or with individual investigators in our research programs.  Usually more limited in scope than a DBP, initial collaborations can easily grow into a full-fledged DBP.  Please contact specific investigators within the Center.

Industry Partnerships:  We have partnered with several companies, including Thermo, Inc., to implement our analytical platform for glycan analysis that includes glycoinformatic database searches data processing. Our goal is to integrate our platform with proteomics such that an RO1 researcher, for example, can determine the glycan expression on a mixture of glycoproteins.

As we are preparing for our competitive renewal of the P41 grant, we have made some adjustments in the structure of the Center. The internal platform we have used is that of human embryonic stem cells (hESC) and induced pluripotent stem cells from patients with several Congenital Disorders of Glycosylation which are differentiated down several lineages to produce well-characterized cell types, such as neural crest cells and definitive endoderm.

Our TR&D1 Glycoanalytics will develop high-throughput, automated quantitative analysis of glycans and enhanced site-mapping of glycans expressed on glycoproteins, as well as tools to enrich cell surface glycoconjugates and to label glycoconjugates for quantification using metabolic isotopic labeling. Multiplexed RNA Seq and high-throughput qRT-PCR data will be input into software with TR&D2 (GRITS) for visualization and integration of glycan structural data and transcriptome analysis. We have partnered with two industry partners and several analytical laboratories to assist in the development and dissemination of our tools.

TR&D2 Glycoinformatics will complete the development of a Glycoanalytics Platform that will store, organize, and disseminate searchable peptide, glycan, and transcript data sets.  The portal will allow biomedical researchers to query the glycosylation of specific glycoproteins (such as receptors) in various cell types developed by TR&D3 Tools for targeting glycan processing pathways, which will develop a novel reporter hESC line expressing several tagged secreted and membrane-bound reporter glycoproteins that will facilitate identifying subtle glycan changes as cells are differentiated down several lineages. Utilizing the Metscape app within the Cytoscape platform for network analysis, a Glycan Pathway Visualization (GPV) tool will be developed that integrates data display and features annotation in a single unified interface using custom pathways. This tool will be particularly useful for researchers who are relatively unfamiliar with glycan biosynthesis to visualize and understand the effects of alterations in the glycome in development and disease.  As part of Community Engagement, we will utilize several innovative means to grow our already extensive client base.

org chart

“We gratefully acknowledge the support of the National Center for Biomedical Glycomics at the University of Georgia by a grant from the National Institute of General Medical Sciences (GM103490) and National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.”